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A
lthough it may surprise scientists, 
one can receive a patent in many 
jurisdictions without implementing 
an invention in practice and dem-
onstrating that it works as expected. 
Instead, inventors applying for pat-
ents are allowed to include predicted ex-
perimental methods and results, known as 
prophetic examples, as long as the exam-
ples are not written in the past tense (1–3). 
Allowing untested inventions to be pat-
ented may encourage earlier disclosures 
about new ideas and provide earlier cer-
tainty regarding legal rights—which may 
help small firms acquire financing to bring 
their ideas to market. Yet granting patents 
too early may also discourage research-
ers from doing the work to bring ideas to 
fruition (4, 5). Even if allowing untested 
inventions to be patented is desirable, we 
think prophetic examples deserve closer 
scrutiny, and clearer labeling, because of 
the likelihood that they are unnecessarily 
confusing—particularly to scientists, many 
of whom read patents but are unlikely to 
appreciate that not all the claims are based 
on actual data.
The U.S. Patent and Trademark Office 
(USPTO) formally recognized prophetic 
examples in 1981, but the practice is con-
siderably older. A patent application need 
only contain sufficient information that a 
skilled researcher in the field would rec-
ognize as credibly demonstrating how to 
make and use the invention (6). Prophetic 
examples are one way to help satisfy this 
legal standard for inventions that have 
not yet been demonstrated to work (2). Al-
though prophetic examples that are close 
variations on actual experiments are pref-
erable, many prophetic examples appear 
to be entirely hypothetical predictions. 
Preliminary research suggests that these 
examples are particularly prevalent in 
chemistry and biology; an estimated 17% 
of examples in U.S. patents in these fields 
are prophetic, and almost one-quarter of 
U.S. patents in these fields have at least 
one prophetic example—making prophetic 
examples a commonplace feature (for ex-
amples, see the box) (7).
Because of concerns about awarding 
patents to unproven inventions, prophetic 
examples are viewed with greater skepti-
cism in Europe (8), Canada (9), Japan (10), 
and China (11). However, because patents 
with the same contents are often filed 
in multiple regions, prophetic examples 
originating in U.S. applications will often 
be present in applications filed in other ju-
risdictions. Further, because patent offices 
and examiners in those countries com-
monly read and cite patents from other 
jurisdictions, countries skeptical of pro-
phetic examples still feel their effects.
PROPHETIC EXAMPLES MAY BE CONFUSING
Contrary to the assertions of some patent 
scholars that scientists never read pat-
ents, survey evidence shows that many re-
searchers do look to the patent literature 
for general research, to browse informa-
tion about cutting-edge technologies, and 
to learn how other researchers solved par-
ticular problems (12). Training on how to 
search patents is even provided in some 
undergraduate science classes (12). But the 
usefulness of patents as a source of techni-
cal information is diminished if scientific 
readers are unable to distinguish actual 
data from predicted results.
Although scientists read patents—and 
therefore also read prophetic examples—
the verb tense rule that distinguishes these 
predicted results from actual data is un-
likely to be familiar to the average scien-
tist. Most patent drafters do not seek to 
intentionally mislead readers, but they are 
writing for a legal audience and using con-
ventions that may be unclear to nonlegal 
readers. Prophetic examples are confusing 
because they mimic real experiments, par-
ticularly by including excessive detail—for 
example, age of the hypothetical patient (“a 
46-year-old woman…”)—and specific, nu-
merical results (“blood pressure is reduced 
within 3 hours…”). Some preliminary work 
suggests that of 100 randomly selected pat-
ents with only prophetic examples—that is, 
no actual data—that were cited in a scien-
tific article or book for a specific proposi-
tion, 99 were not cited in a way that made 
clear that the cited information was pro-
phetic (7). To the contrary, these prophetic 
patents were cited with phrases such as 
“[d]ehydration reaction in gas phase has 
been carried out over solid acid catalysts” 
(7), suggesting that prophetic examples 
mislead scientist readers.
Prophetic examples may also be confus-
ing to other readers who are unfamiliar 
with the tense rule, such as investors seek-
ing to accurately evaluate complex technol-
ogies. Causing further misunderstanding, 
the subtlety of prophetic examples may 
literally be lost in translation for patent 
applications that must be translated into 
different languages because they are filed 
in international jurisdictions. To be sure, 
quantifying the cost of this confusion would 
be challenging, especially because most 
confused scientists, investors, and patent 
examiners are likely unaware of the prob-
lem. But given the lack of a corresponding 
benefit, there seems to be no reason to per-
petuate the practice. Nothing in patent law 
requires early-stage ideas to be described in 
a way that might confuse these different au-
diences by mimicking factual experiments; 
prophetic examples could be signaled more 
clearly or avoided altogether.
WHY USE PROPHETIC EXPERIMENTS?
To explore whether benefits for patentees 
from prophetic examples can be obtained 
through less confusing patent-drafting 
methods, we interviewed professional pat-
ent prosecutors who write U.S. patents. As 
described in the supplementary materials, 
we identified prophetic examples as those 
written in the present or future tense. We 
then contacted a randomly selected sample 
of patent prosecutors in the fields of chem-
istry and biology who, in patent applica-
tions filed between 2011 and 2013, either 
never used prophetic examples or used 
prophetic examples in more than half of 
applications filed. We conducted 26 inter-
views, with a yield rate of 67%.
Prosecutors who use prophetic examples 
consistently explained that such examples 
make clear how an inventor expects an idea 
to work in scenarios for which there is not 
time or money to test before the desired 
patent filing deadline. Because patents 
can cover all variations of an invention 
described in enough detail for others to 
make and use without undue experimen-
tation, prophetic examples with predicted 
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results can extend the patent’s legal pro-
tection. For example, if an inventor has 
made a particular protein in her labora-
tory but also believes that the protein will 
work similarly if certain amino acids are 
switched, a prosecutor can draft prophetic 
examples with the alternate sequences 
and a prediction of the expected outcome. 
These examples help the inventor obtain 
patent coverage beyond the specifics of 
what has been done in the laboratory, in-
cluding to block competitors from working 
on similar technologies.
Interviewed prosecutors generally ac-
knowledged the possibility that scientists 
reading prophetic examples might be un-
able to correctly interpret the verb tense 
rule, although they emphasized the legality 
of the practice and their duty to obtain the 
strongest possible patent for their clients. 
They also agreed, however, that an equally 
strong patent could be obtained with 
prophetic examples that were explicitly 
labeled as predictions that had not been 
carried out. Interviewees who do not use 
prophetic examples argued that there is no 
legal reason to present these predictions 
in the form of fictitious experiments with 
specific results rather than in more gen-
eral terms; to the contrary, prophetic ex-
amples carry some legal risk, such as if the 
example turns out to be inoperative. Pros-
ecutors were particularly wary of using 
prophetic examples in patent applications 
that would be filed internationally, given 
the greater skepticism of these examples in 
certain countries.
The only benefit to patentees that would 
be reduced by requiring greater clarity 
seems to be the benefit that comes from 
confusion. For example, several prosecu-
tors suggested that prophetic examples 
could illustrate a technology’s promise to 
potential investors, who might not be able 
to distinguish between prophetic examples 
and experiments actually conducted. This 
potential confusion was considered a ben-
efit to patentees, but this benefit does not 
seem worth preserving.
MORE CLARITY, LESS CONFUSION
The benefits flowing from prophetic ex-
amples exist because some patent systems 
recognize and allow the use of hypothetical 
experiments and data. Within these legal 
systems, prosecutors, patent examiners, 
and courts can already identify prophetic 
examples through the tense rule, so requir-
ing a more explicit distinction between 
prophetic and nonprophetic examples 
would have no legal impact; prophetic ex-
amples would continue to be recognized 
and rewarded as such, just with lower risk 
of confusion.
The impact of clarifying prophetic ex-
amples would also be felt outside the legal 
systems that allow the practice. Scientists 
previously unable to distinguish or unaware 
of the distinction between prophetic and 
real experiments would gain more informa-
tion and clarity. Investors using patents as a 
source of information about new technolo-
gies would find such information clearer 
and more useful. And international patent 
offices wrongly interpreting prophetic ex-
amples when tenses are lost in translation 
would be able to avoid such errors.
What should be done? A simple and ef-
fective solution is to require that prophetic 
examples in new patent applications be 
clearly labeled, perhaps with a heading 
such as “hypothetical experiment” or an 
introductory phrase such as “it is expected 
that these experiments would provide 
these results.” In the United States, for ex-
ample, this change could be implemented 
by the USPTO along with its other rules for 
patent formatting. The USPTO already re-
quires that prophetic examples be labeled 
(by avoiding the past tense), so our pro-
posal does not add a labeling requirement; 
it merely makes an existing requirement 
more effective. Further, patent drafters 
should be encouraged to be mindful of 
clarity and avoid potentially confusing 
phrases and details.
Just because some patents are not based 
on actual results does not mean they need 
to be confusing. Scientists regularly write 
grant applications in a way that makes 
clear what preliminary data they have al-
ready acquired and what the expected goal 
of the proposed project is. Perhaps this is 
an area in which the patent system could 
learn from the scientific community.  j
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10.1126/science.aax0748
Patently Prophetic
The present tense used in patents 
for a chemical synthesis, a medical 
procedure, and a medical device sug-
gests that the procedures likely had not 
actually been conducted at the time of 
filing a patent application.
U.S. Patent 
No. 3,931,205
2.5 g of 2-(5H-[1]
benzopyrano[2,3-b]
pyridin-7-yl)acrylic acid 
is dissolved in 20 ml of 0.5 
N aqueous sodium hydroxide solution, 
and 1 g of Raney nickel is added. The 
solution is stirred in a hydrogen stream 
at ordinary pressure and temperature 
until absorption of 230 ml of hydrogen 
is attained. The Raney nickel is removed 
by filtration, and the filtrate is neutral-
ized with hydrochloric acid. The resulting 
crystalline precipitate is filtered off, 
washed with water, and recrystallized 
from aqueous dioxane to give 1.8 g of 
2-(5H-[1]benzopyrano[2,3-b]pyridin-7-yl)
propionic acid melting at 183° –184°C.
U.S. Patent 
No. 6,869,610
A 46-year-old woman 
presents with pain 
localized at the deltoid 
region due to an arthritic con-
dition. The muscle is not in spasm, nor 
does it exhibit a hypertonic condition. 
The patient is treated by a bolus injec-
tion of between about 50 units and 200 
units of intramuscular botulinum toxin 
type A. Within 1 to 7 days after neuro-
toxin administration the patient’s pain is 
substantially alleviated. The duration of 
significant pain alleviation is from about 
2 to about 6 months.
U.S. Patent 
No. 7,291,497
Each patch [for 
drawing and sampling 
0.1 ml of blood for 
vancomycin] consists of two 
parts. … Micro-needles automatically 
draw small quantities of blood pain-
lessly. A mechanical actuator inserts 
and withdraws the needle … mak[ing] 
several  measurements after the patch 
is applied. … Needles are produced 
photolithographically in molds at [the 
Stanford Nanofabrication Facility]. … 
Blood flows through the micro-needles 
into the blood reservoir. …
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